retatrutide phase 2 trial results weight loss just delivered one of the largest weight-loss signals Retatrutide, a TRIPLE agonist (GLP1,

Retrieved from Jouanne, M., Oddoux, S., Nol, A., et al

Svensson, P

The company offers the most popular GLP-1 treatments Ozempic, Wegovy and Zepbound at a discounted rate from the two biggest players in the game Eli Lilly and Novo Nordisk

The 2025 data is genuinely encouraging but still early much of it is retrospective or database-based, not randomized trials in RA

Indeed, most participants in the PASADENA trial experienced a meaningful motor progression milestone (5-point worsening in MDS-UPDRS Part III) before starting their symptomatic therapy

Ten GLP-1 drugs are FDA-approved to treat either type 2 diabetes or weight loss